Objectives: The association of new-onset postoperative atrial fibrillation (POAF) and late death after coronary artery bypass grafting (CABG) has been confounded by the frequent concomitant serious complications that cooccur with POAF. We aimed to define the magnitude and time dependence of the effect of isolated POAF on late survival after uncomplicated CABG to comprehensively account for comorbidity and perioperative confounding factors.
ischemia, and a predisposing anatomic substrate has been implicated in PAOF; however, the exact pathophysiology of POAF is poorly understood. The incidence of POAF after coronary artery bypass grafting (CABG; 15%-40%) has reportedly been predicted by patient demographics, including older age, lower ejection fraction, hypertension, heart failure, prolonged cardiopulmonary bypass, enlarged left atrium, perioperative medications, and enhanced inflammatory and oxidative stress. [7] [8] [9] [10] A number of recent studies have extended the adverse effects of POAF after CABG to include significantly worse late mortality. 2, 9, [11] [12] [13] [14] [15] [16] If true, this finding is of substantial clinical importance, given the high incidence of POAF; however, the specific mechanism by which an ostensibly limited perioperative arrhythmia, such as POAF, affects long-term survival is unclear. The available evidence on this POAF-late mortality association has been limited by the nonuniformity of the analyses and findings and/or incomplete accounting for known determinants of late mortality after CABG. No studies, thus far, account for (1) extent of arterial grafting and (2) completeness of coronary revascularization. [17] [18] [19] [20] [21] [22] Furthermore, homologous blood product transfusion, which has been notably more frequent in patients with a greater likelihood of POAF and has been identified as a predictor of late mortality has also been largely ignored in studies of the effects of POAF. [23] [24] [25] In addition, POAF has frequently been associated with other serious postoperative complications. Consequently, the interplay between these nonarrhythmic complications and POAF might have confounded the independent effects of these conditions on operative and, possibly, late death. 2, 8, 9, 11 Separating the late effects of POAF and concurrent complications is difficult, and studies, thus far, have either ignored this 13, 26 or have relied on multivariate Cox regression modeling to account for some, but not all, such complications. 2, 9, 11, 14, 27 Finally, the potentially time-varying POAF effect on late mortality, its duration, and the period of greatest risk has not been described.
Within this construct, we reasoned that if POAF independently leads to increased late CABG mortality, it should do so even (1) in the absence of other nonarrhythmic postoperative complications, and (2) after more comprehensive adjustment for other known pre-, intra-, and postoperative predictors of late survival. Accordingly, we investigated the POAF-late CABG survival association in a manner that avoids these limitations by more comprehensive accounting of patient variables, operative and grafting details, transfusion status, and, most importantly, by excluding patients with other complications.
METHODS
The present investigation was a retrospective analysis of a prospectively collected data from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. The Mercy Saint Vincent Medical Center (Toledo, Ohio; 1994-2007) institutional review board approved our study. Data collection was performed in compliance with the Society of Thoracic Surgeons Database definitions and criteria and did not involve an additional review of the hospital records or interviewing the patients; thus, the informed consent requirement was waived.
Patients
Patients undergoing isolated CABG from 1994 to 2007 were included in the present analysis. CABG patients with concurrent coronary or carotid reconstruction were also included. Patients were excluded in the case of concomitant valvular, congenital cardiac or aortic surgery, a documented history of preoperative atrial fibrillation (AF) or atrial flutter, or emergency salvage status. A total of 7610 patients qualified for inclusion, and these patients were subsequently grouped as follows: (1) 5094 patients, who had not developed POAF or any other postoperative complication (no-AF; control group); (2) 1211 patients with isolated POAF without other complications (AF; study group); (3) 832 patients without POAF but who had developed other complications (no-AF/C); and (4) 473 patients, who had developed POAF and other complications (AF/C). To mitigate any potential confounding effects of concurrent non-rhythm-related perioperative complications on long-term survival, the subcohort of patients without any other perioperative complications, aside from POAF, was selected as the principal focus of the present investigation. Time 0 was defined as the time of discharge. In-hospital deaths were considered the same as patients with complications and were therefore excluded from the AF and no-AF groups. POAF was defined, as per the Society of Thoracic Surgeons Database, as the occurrence of POAF or atrial flutter requiring treatment (ie, b-blockers, calcium channel blockers, amiodarone, anticoagulation, or cardioversion) throughout hospitalization or at readmission within 30 days postoperatively. Telemetry was used in 100% of the patients during hospitalization.
Surgery
Our surgical techniques have been previously reported. 17, 19 Cardiopulmonary bypass (96%) and aortocoronary grafting (97%) were used in a large majority of patients. Evidence-based critical pathways were used and periodically updated, in compliance with emerging data documented to optimize outcomes, improve care, or decrease resource usage. Treatment of POAF, if it occurred, is described in the Online Data Supplement. All efforts were made to discharge patients in a normal sinus rhythm. Patients discharged in rate-controlled AF were routinely discharged with warfarin, unless contraindicated. The database is not granular enough to derive the subset of patients with POAF discharged in a non-sinus rhythm.
Perioperative Medications
Aspirin and b-blocker use was consistent throughout the 1994 to 2007 study period. In all patients, b-blockers were routinely administered orally until the morning of surgery and, in stable patients, were reinstituted on postoperative day 1. Accordingly, the point of b-blocker withdrawal (if any) was minimized in the present series of patients. An angiotensinconverting enzyme inhibitor was used routinely in patients with normal renal function, including those who had been taking 1 preoperatively, who had a history of congestive heart failure, or who had a low ejection fraction (<35%), if hemodynamically tolerated (systolic blood pressure >100 mm Hg) in the early phases of the study period and routinely in the later phase of the study period in compliance with the practice guidelines. Aspirin (325 mg by way of a nasogastric tube) was always given to patients on arrival at the cardiovascular intensive care unit and was decreased to 162 mg orally daily on postoperative day 1. Amiodarone (intravenous or orally), once approved for clinical use, was routinely used after the onset of AF, including intraoperatively. Starting in July 1999, prophylactic amiodarone was used routinely in all patients (200 mg daily by mouth started on postoperative day 1). Before the availability of amiodarone, quinidine and/or procainamide, in conjunction with calcium channel antagonists, were used to treat POAF.
Follow-up
All-cause mortality was secured from the cardiothoracic surgery followup data and verified from scheduled searches of the US Social Security Death Index database (available at: http://ssdi.genealogy.rootsweb.com), last performed in November 2011. The follow-up period was 56 (minimum) to 214 (maximum) months. The AF and no-AF groups exhibited significant demographic and risk factor differences (Table 1 and Table E1 ). Such differences confounded the outcome comparisons in observational comparison groups. To minimize such confounding, we used propensity score matching to derive demographic-, risk factor-, and operation-matched subcohorts of equal size. The propensity score, or equivalently the probability that a given patient would develop POAF, was derived by a nonparsimonious logistic multivariate regression model that considered POAF status (AF or no-AF) as the dependent outcome variable. A total of 55 preoperative risk factors (Tables 1 and E1 ), demographic data, and operative variables were entered into the model, irrespective of significance. The completeness of revascularization index (number of grafts minus the amount of vessel disease) was derived from the difference between the number of grafts (number of grafts or distal anastomoses in the case of sequential grafts) and coronary vessel disease. The year of surgery was entered as a continuous year of series variable (1994 ¼ 1; 2007 ¼14) to account for potential variance in reporting POAF or its treatment. Highly redundant variables were avoided. The resulting propensity scores were distinctly different for isolated AF versus no-AF patients (mean AE SD, 0.259 AE 0.124 vs 0.176 AE 0.106, respectively; P<.001). The corresponding C-statistic value was 0.703 AE 0.008, indicating moderately good discrimination. Next, a custom-made computer algorithm was used to obtain propensity matched pairs. Given the abundance of no-AF patients, we considered 1-to-1 (single match), 1-to-2 (double match), and 1-to-3 (triple match) matched pairings. The AF patients were always matched to the closest available no-AF counterpart (AE1%). The adequacy of matching was assessed using the standardized difference [d(%)]. 28 
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Statistical Analysis
Continuous and categorical data are expressed as the mean AE standard deviation or frequencies and percentages, respectively. Univariate comparisons before matching were performed using the chi-square, unpaired t test, and Mann-Whitney rank test, as appropriate. Unadjusted and matched survival comparisons were done using Kaplan-Meier analysis (log-rank). The ratios of the cumulative death hazard as a function of time were calculated after time imputation of the calculated hazard functions. Given the observed nonproportional hazards, the AF effect was quantified in 2 ways: (1) time-segmented hazard ratios (HRs) and 95% confidence intervals (CIs) using Cox regression analysis, and (2) time-averaged HRs derived from the calculated ratio of the cumulative death hazard functions. Analyses were performed using the Statistical Package for Social Sciences, version 21.0, software (IBM Corp, Armonk, NY).
RESULTS
All Patients
One or more postoperative complications were documented in 2516 of 7610 CABG patients (33.1%), including POAF in 1684 patients (22.12%). Of the latter, 1211 patients with isolated POAF (15.9%) formed the AF group. The no-AF control group included the remaining complicationfree patients (n ¼ 5094 [66.9%]). The incidence of POAF in patients experiencing nonarrhythmic complications other than isolated POAF was 36.2% (473 of 1305) compared with the 22.2% incidence of POAF in the entire CABG cohort. The incidence of POAF in the no-complication cohort was 19.2% (1211 of 6305). The patients with POAF accounted for 66.9% of all patients with any postoperative complication. The documented incidence of POAF increased from 13% (1994) to around 28% (2006) (2007) .
The patients with AF were generally older, with a larger body habitus, had more comorbidities, required more blood transfusions, and had a different coronary grafting profile (Table 1) . They also had a greater use of preoperative b-blockers, digitalis, and diuretic medication. POAF was independently predicted by older age, a large body surface area, peripheral vascular disease, a history of cerebrovascular accident, chronic lung disease, reoperation, and preoperative intra-aortic balloon pump use (Table E2) . Off-pump surgery decreased the risk of POAF.
The patients were followed up for an average of 9.7 AE 4.2 years, and the unadjusted 18-year survival was significantly worse in those with AF, whether accompanied by complications or not (Figure 1 ).
Matched Patients
Propensity score matching yielded 1196 AF/no-AF pairs (single-match) that were well-matched with relatively small, nonsignificant percentage of differences for all factors ( Table 1 ). The cumulative mortality was worse for the AF group than for the no-AF group (Figure 2 ). The corresponding ratios of the cumulative death hazard functions varied with time ( Figure 3 ; single-match), and the timeaveraged HR estimates varied from 1.11 (0-1 years), 1.27 (1-6 years), to 1.28 (6-17 years; Table 2 and Figure 3) . Finally, the HRs estimated using time-segmented Cox regression analysis (3 phases) varied similarly: 1.18 (0-1 years) to a maximum of 1.37 (1-6 years) and 1.25 (6-17 years; Table 2 ). The estimates of the AF effect were consistent for the double (1:2) and triple (1:3) matched comparisons ( Figure 2 and Table 2 ).
DISCUSSION
The results reported in the present study support the emerging view that POAF is a ''malignant'' process that adversely affects long-term survival in patients undergoing otherwise uncomplicated CABG surgery, with the postoperative death HR reaching a peak within 2 years of the index operation and gradually decreasing to unity during the next decade and a half postoperatively. By focusing on a subcohort of CABG patients who had experienced no other perioperative complications other than POAF, any potential confounding interplay effects between POAF and other acute perioperative adverse events were minimized. The pathophysiology behind our observations remains perplexing and obscure.
The multiple analyses we applied indicated that isolated POAF increases the 18-year mortality in a time-varying fashion in patients undergoing uncomplicated CABG. The consistency of our findings for the single-, double-, and triple-matched comparisons indicated that our finding was robust (Table 2 ) and was generally in line with the lower to middle range of previously reported POAF effects (Table 3) . 2, 9, [11] [12] [13] [14] [15] The present analysis is the first to An important aspect of our study was that it controlled for several limitations characterizing the previous related analyses. The effect of arterial grafting, completeness of revascularization, and blood transfusion was adjusted for in our multivariate and propensity modeling. None of the previous POAF reports considered the known effects of arterial grafts or the completeness of revascularization on the late outcomes of CABG. [19] [20] [21] [22] This is particularly relevant given that POAF is more frequent in older patients who are also less likely to receive multiple arterial grafts and, generally, will have had a lower number of grafts constructed. 20 Similarly, most previous studies did not account for the association between the perioperative use of blood products and worse late mortality. [23] [24] [25] Also, thus far, the reported analyses have not adequately accounted for whether the POAF episode was or was not accompanied, preceded, or followed by other perioperative complications that, themselves, have important independent, or potentially cumulative additive, effects on the long-term outcomes. Not surprisingly, given the increased physiologic stress and longer length of stay associated with non-POAF postoperative complications, we noted that the incidence of POAF in patients experiencing other postoperative complications was nearly twice the rate of isolated POAF in patients without other complications (36.2% vs 19.2%) and greater than the rate of POAF in the overall CABG group (36.2% vs 22.1%). Wang and colleagues 29 have identified a similar trend among medical patients whose comorbidities affect the effects of atrial fibrillation and vice versa. Finally, and, perhaps most significantly, we are aware of no other studies that specifically examined the temporal relationship of the POAF-late mortality association, the evaluation of which could be useful in attempting to identify the mechanisms behind POAF's malignant effects. These limitations of the previous analyses collectively were the impetus for the present analysis.
Despite the increasing attempts at preventative measures during the study period, notably, with the routine implementation of prophylactic amiodarone therapy and b-blocker therapy, the incidence of POAF increased during the study period from only 13% in 1994 to 28% in 2007. The changing profile of the CABG population and/or more vigilant capture of transient burst POAF concurrent with more sensitive telemetry technology could ostensibly have been responsible for such a trend. The predictors of POAF defined in the present study have corroborated the findings of other studies 30 and included older age, larger body surface area, peripheral vascular disease, history of cerebrovascular accident, chronic obstructive pulmonary disease, reoperation, and the need for an intra-aortic balloon pump. In contrast to the findings from Almassi and colleagues, 16 we found that the off-pump CABG technique was protective against POAF. We did not have routine echocardiographic data available to assess whether diastolic dysfunction was associated with POAF, a finding previously reported by Tsang and colleagues 31 in nonsurgical patients and suggesting a possible pre-existing cardiac substrate for POAF.
The proposed explanations for why and how POAF increases long-term CABG mortality remain highly speculative. It is not immediately clear why POAF, presumed to be a short-lived, nonrecurring postoperative event, would increase long-term mortality for up to or beyond 10 years after surgery. Conceivably, POAF might be a marker for patients at increased risk of repeated episodes of AF after discharge that might lead to chronic AF, a condition well known to (1) (2) (3) (4) (5) (6) , HR t at 1 to 6 years postoperatively; HR t (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , HR t at 6 to 17 years postoperatively; CABG, coronary artery bypass grafting. Data presented as cumulative hazard ratios, with 95% confidence intervals in parentheses. *Non-model-based, estimated from the actual ratio of the cumulative hazard functions derived from the matched AF and no-AF subcohorts.
adversely affect long-term survival. Although logically appealing, given the high rate of AF progression in medical patients along the spectrum from paroxysmal to persistent to long-standing persistent AF, 32 such a relationship has not been defined in cardiac surgical patients and could be a fruitful area for additional studies. Alternatively, POAF might reflect a subclinical, and as yet undefined, disease process that affects the atria that then, in turn, could adversely affect long-term survival. The finding that an atrial electromechanical interval of >120 ms predicted the development of POAF with 100% sensitivity and 94% specificity suggests such an underlying structural abnormality, 33 although its clinical significance remains undefined. Finally, it is possible that POAF is simply a surrogate marker for an unknown systemic process that decreases long-term survival. The intriguing results of our analysis documenting the maximal risk of POAF-associated mortality within 2 years of the index surgery suggests a permissive effect of the perioperative perturbations in homeostasis and whatever process might underlie POAF. Whether aggressive POAF prophylaxis, its more aggressive treatment, or its much closer follow-up during the period of greatest risk would ameliorate its adverse effects was beyond the scope of the present study. Our study findings have, however, added to the growing body of data supporting the adoption of a more aggressive search for the underlying pathophysiology of POAF, rather than just focusing on more aggressive treatment options of POAF as a productive method of reducing late mortality.
One reasonable next step would be to more closely follow-up patients with POAF, with the goal of assessing whether this perioperative arrhythmia leads to, or reflects, long-term cardiac electrophysiologic abnormalities and/or altered atrial transport properties, both of which could conceivably lead to an increased risk of subsequent thromboembolic events. The increasingly simplified outpatient rhythm monitoring capabilities has made this an attractive and relatively inexpensive option, particularly in light of the results of the Framingham study, which reported significantly greater mortality in patients affected by chronic AF than those without AF (1 year, 18% vs 5.9%; and 10 year, 61.5% vs 30%). 34 The documented adjusted risk of stroke, which was substantially increased to 2.6-to 4.5-times greater in patients with AF, 34, 35 was thought to result from an impaired atrial to ventricular transport function, resulting in blood stasis, with subsequent left atrial appendage thrombus formation. The observation from ElChami and colleagues 14 that patients developing POAF after CABG who were discharged with warfarin were found to have a lower mortality rate supports the supposition that the adverse effects of POAF might be based on a thromboembolic phenomenon. Alternatively, reduced cardiac output from the loss of the ''atrial kick'' inherent in AF might lead to impaired cerebral circulation and increase the risk of noncardioembolic stroke. 36 Mariscalco and colleagues 2 linked the increased 7-year mortality in patients developing POAF after CABG to increased thromboembolic sequelae. In that study, POAF increased the risk of mortality two-to threefold and was associated with greater cardiac death (by a factor of 3) and disabling embolic events (by a factor of 4). Whether these complications are associated with a minimum threshold of arrhythmic burden, are a function of the total time in non-sinus rhythm, or, possibly, result from a specific number of conversions between AF and sinus rhythm has not been defined. This could represent yet another area for future investigations, given the increasing sophistication of technologies available for monitoring patients after discharge from the hospital.
Study Limitations and Strengths
Our study had a number of limitations, including its observational retrospective nature, which could have been associated with possible residual confounding effects of both measured and unmeasured variables. It was also a single practice series, which could limit its generalizability.
Other limitations included that we were unable to analyze (1) the effects of prescribed medications in patients with AF (eg, warfarin, amiodarone, other antiarrhythmic agents); (2) the duration and number of episodes of AF and whether POAF was successfully cardioverted or whether the patient was discharged in rate-controlled AF; (3) the temporal relationship between complications and the incidence of AF and the possibility that complications that might have occurred after AF would probably have led to an underestimation of the true effect of AF on subsequent mortality, because such cases were excluded from our study; (4) the postdischarge incidence or persistence of AF; and (5) the effect of the evolving and changing treatment modalities of POAF on late outcomes, because the exact times of protocol-driven perioperative management changes were not available to us. Our database was not sufficiently granular to allow us to account for functional completeness of revascularization, which requires information on all areas of ischemia. Our applied approach might not be optimal for cases such as sequential grafting or multigrafts to same territory. Most importantly, perhaps, the cause-of-late-death data were also not routinely available to further elucidate the specific mechanism underpinning the association of POAF and increased late mortality.
CONCLUSIONS
Our results support the contention that postoperative isolated POAF in uncomplicated CABG patients is not a benign postoperative event but, rather, is associated with a timevarying increased risk of late mortality, peaking at 1 to 6 years and decreasing afterward but remaining elevated for the AF cohort during 18 years of follow-up. This effect was found even when the potential confounding effects of the interplay between POAF and other postoperative complications were effectively eliminated. Although the significant associated mortality might seem relatively modest in magnitude, its effect on loss of life years was large, given the high incidence of POAF (20%-40%) after CABG. Accordingly, we recommend more rigorous follow-up of patients who experience POAF above and beyond the current levels, focusing on the potential development of electrophysiologic or atrioventricular transport function abnormalities as potential fruitful research areas aimed at elucidating the specific etiologic role of POAF on long-term survival.
ARIAL FIBRILLATION MANAGEMENT Prophylaxis
With the emergence of data supporting amiodarone as postoperative atrial fibrillation (POAF) prophylaxis in the latter half of the 1990s, all our patients were routinely treated with amiodarone starting on postoperative day 1 and continued for 8 weeks postoperatively, unless the patient had contraindications. The usual dose was 200 mg orally, twice daily. b-Blockers were routinely prescribed postoperatively and were continued indefinitely. In patients with bradycardia, amiodarone was withheld preferentially over b-blockers.
Atrial Fibrillation Treatment
Before 1997, POAF was treated with a combination of calcium channel antagonists and dioxin for rate control and procainamide for rhythm conversion.
Hemodynamically unstable POAF was treated with direct current electrical cardioversion.
After 1997, POAF was treated with intravenous amiodarone for acute rate and rhythm control and was transitioned to oral dosing after conversion to sinus rhythm. Oral amiodarone was continued for 8 weeks postoperatively. In the few patients with persistent rapid POAF despite intravenous amiodarone, a intravenous diltiazem was added for rate control. This regimen resulted in fewer than 5% of patients with POAF being discharged from the hospital in a nonsinus rhythm. Direct current electrical cardioversion for rhythm control was used very rarely. Warfarin therapy was instituted only for those patients who remained in POAF for at least several days or who continued to document multiple sustained bursts of POAF despite maximally aggressive pharmacologic treatment. If sinus rhythm was restored after hospital discharge, warfarin was discontinued at 8 weeks postoperatively. 
